Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 60


Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators.

J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1.


Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection.

Kolberg M, Høland M, Lind GE, Ågesen TH, Skotheim RI, Hall KS, Mandahl N, Smeland S, Mertens F, Davidson B, Lothe RA.

Mol Oncol. 2015 Jun;9(6):1129-39. doi: 10.1016/j.molonc.2015.02.005. Epub 2015 Feb 18.


EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.

Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM, Krailo M, Anninga J, Butterfass-Bahloul T, Böhling T, Calaminus G, Capra M, Deffenbaugh C, Dhooge C, Eriksson M, Flanagan AM, Gelderblom H, Goorin A, Gorlick R, Gosheger G, Grimer RJ, Hall KS, Helmke K, Hogendoorn PC, Jundt G, Kager L, Kuehne T, Lau CC, Letson GD, Meyer J, Meyers PA, Morris C, Mottl H, Nadel H, Nagarajan R, Randall RL, Schomberg P, Schwarz R, Teot LA, Sydes MR, Bernstein M; EURAMOS collaborators.

Ann Oncol. 2015 Feb;26(2):407-14. doi: 10.1093/annonc/mdu526. Epub 2014 Nov 24.


Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis.

Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Sundby Hall K, van den Berg E, Mertens F, Smeland S, Picci P, Lothe RA.

Neuro Oncol. 2015 Jan;17(1):63-9. doi: 10.1093/neuonc/nou140. Epub 2014 Jul 19.


An educational program to transition oncology nurses at the Norwegian Radium Hospital to an evidence-based practice model: development, implementation, and preliminary outcomes.

Bruheim M, Woods KV, Smeland S, Nortvedt MW.

J Cancer Educ. 2014 Jun;29(2):224-32. doi: 10.1007/s13187-013-0575-9.


Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Follow-Up Study.

Russnes KM, Wilson KM, Epstein MM, Kasperzyk JL, Stampfer MJ, Kenfield SA, Smeland S, Blomhoff R, Giovannucci EL, Willett WC, Mucci LA.

Int J Cancer. 2014 Mar 1;134(5):1156-65. doi: 10.1002/ijc.28438. Epub 2013 Nov 11.


Incidence and mortality of second sarcomas - a population-based study.

Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Bruland ØS, Smeland S, Johannesen TB, Fosså SD.

Eur J Cancer. 2013 Oct;49(15):3292-302. doi: 10.1016/j.ejca.2013.05.017. Epub 2013 Jun 17.


Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis.

Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, Kager L, Kühne T, Sydes M, Gelderblom H, Ferrari S, Picci P, Smeland S, Eriksson M, Petrilli AS, Bleyer A, Thomas DM.

J Clin Oncol. 2013 Jun 20;31(18):2303-12. doi: 10.1200/JCO.2012.43.8598. Epub 2013 May 13.


Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Kolberg M, Høland M, Agesen TH, Brekke HR, Liestøl K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA.

Neuro Oncol. 2013 Feb;15(2):135-47. doi: 10.1093/neuonc/nos287. Epub 2012 Nov 15. Review.


Stress associated gene expression in blood cells is related to outcome in radiotherapy treated head and neck cancer patients.

Bøhn SK, Russnes KM, Sakhi AK, Thoresen M, Holden M, Moskaug JØ, Myhrstad MC, Olstad OK, Smeland S, Blomhoff R.

BMC Cancer. 2012 Sep 25;12:426. doi: 10.1186/1471-2407-12-426.


Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.

Luksch R, Tienghi A, Hall KS, Fagioli F, Picci P, Barbieri E, Gandola L, Eriksson M, Ruggieri P, Daolio P, Lindholm P, Prete A, Bisogno G, Tamburini A, Grignani G, Abate ME, Podda M, Smeland S, Ferrari S.

Ann Oncol. 2012 Nov;23(11):2970-6. doi: 10.1093/annonc/mds117. Epub 2012 Jul 5.


Bother problems in prostate cancer patients after curative treatment.

Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S.

Urol Oncol. 2013 Oct;31(7):1067-78. doi: 10.1016/j.urolonc.2011.12.020. Epub 2012 Feb 16.


Cancer risk with folic acid supplements: a systematic review and meta-analysis.

Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M.

BMJ Open. 2012 Jan 12;2(1):e000653. doi: 10.1136/bmjopen-2011-000653. Print 2012.


Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival?

Bjerkehagen B, Småstuen MC, Hall KS, Skjeldal S, Smeland S, Fosså SD.

Br J Cancer. 2012 Jan 17;106(2):297-306. doi: 10.1038/bjc.2011.559. Epub 2011 Dec 15.


Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E.

BMC Cancer. 2011 Oct 20;11:455. doi: 10.1186/1471-2407-11-455.


Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones.

Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S.

Prostate. 2012 May 1;72(6):668-76. doi: 10.1002/pros.21470. Epub 2011 Aug 1.


Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.

Smeland S, Bruland OS, Hjorth L, Brosjö O, Bjerkehagen B, Osterlundh G, Jakobson A, Hall KS, Monge OR, Björk O, Alvegaard TA.

Acta Orthop. 2011 Apr;82(2):211-6. doi: 10.3109/17453674.2011.566141. Epub 2011 Mar 24.


Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.

Ferrari S, Sundby Hall K, Luksch R, Tienghi A, Wiebe T, Fagioli F, Alvegard TA, Brach Del Prever A, Tamburini A, Alberghini M, Gandola L, Mercuri M, Capanna R, Mapelli S, Prete A, Carli M, Picci P, Barbieri E, Bacci G, Smeland S.

Ann Oncol. 2011 May;22(5):1221-7. doi: 10.1093/annonc/mdq573. Epub 2010 Nov 8.


Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center.

Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S.

Acta Oncol. 2011 Apr;50(3):408-14. doi: 10.3109/0284186X.2010.492236. Epub 2010 Jun 30.


Postradiotherapy plasma lutein, alpha-carotene, and beta-carotene are positively associated with survival in patients with head and neck squamous cell carcinoma.

Sakhi AK, Bøhn SK, Smeland S, Thoresen M, Smedshaug GB, Tausjø J, Svilaas A, Karlsen A, Russnes KM, Svilaas T, Blomhoff R.

Nutr Cancer. 2010;62(3):322-8. doi: 10.1080/01635580903441188.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk